Bojesen S E, Tybjaerg-Hansen A, Axelsson C K, Nordestgaard B G
Department of Clinical Biochemistry, Herlev University Hospital, Herlev Ringvej 75, Herlev DK-2730, Denmark.
Br J Cancer. 2005 Jul 11;93(1):167-71. doi: 10.1038/sj.bjc.6602674.
To pursue a borderline increased risk of breast cancer for carriers of two integrin beta(3) (ITGB3) 33Pro alleles found in a recent prospective study, we conducted a case-control study of 1088 women with breast cancer and 4815 female controls. Leu33Pro heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers had odds ratios for breast cancer of 1.0 (95% confidence interval: 0.8-1.1), 0.8 (0.5-1.2) and 1.0 (0.8-1.1), respectively. After stratification for conventional risk factors, odds ratio for breast cancer in heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers were not increased above 1.0 in any of the 14 strata examined. This was also true after stratification for tumour histological subtype and cancer stage at the time of diagnosis.
为了探究最近一项前瞻性研究中发现的携带两个整合素β(3)（ITGB3）33Pro等位基因的个体患乳腺癌风险略有增加的情况，我们对1088名乳腺癌女性患者和4815名女性对照者进行了一项病例对照研究。Leu33Pro杂合子、纯合子以及杂合子+纯合子与非携带者相比，患乳腺癌的比值比分别为1.0（95%置信区间：0.8 - 1.1）、0.8（0.5 - 1.2）和1.0（0.8 - 1.1）。在对传统风险因素进行分层后，在检查的14个分层中，杂合子、纯合子以及杂合子+纯合子与非携带者相比，患乳腺癌的比值比在任何一层中均未超过1.0。在对肿瘤组织学亚型和诊断时的癌症分期进行分层后，情况也是如此。
